p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer

被引:77
作者
Ribeiro-Silva, A [1 ]
Ramalho, LNZ [1 ]
Garcia, SB [1 ]
Brandao, DF [1 ]
Chahud, F [1 ]
Zucoloto, S [1 ]
机构
[1] Univ Sao Paulo, Dept Pathol, Fac Med Ribeirao Preto, BR-14049900 Ribeirao Preto, SP, Brazil
关键词
basal phenotype; BRCA1; breast; carcinoma; cytokeratin; 5; cytokeratins; 8/18; p63;
D O I
10.1111/j.1365-2559.2005.02249.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To study the expression of p63, cytokeratin (CK) 5 and CK8/18 in invasive ductal carcinomas and their relationship with BRCA1 and other pathological and immunohistochemical features of clinical significance. Methods and results: Immunohistochemistry with the antibodies p63, CK5, CK8/18, BRCA1, oestrogen receptor, progesterone receptor, p53, c-erbB-2 and Ki67 was performed in 102 formalin-fixed paraffin-embedded samples of invasive ductal carcinomas. The CK5+ cases were submitted to a double-immunolabelling study with p63. There was a strong relationship between CK5 and p63 expression and both markers were associated with hormonal receptor-negative high-grade carcinomas with high proliferative rate. Furthermore, there was coexpression of CK5 and p63 in neoplastic cells, indicating that p63, like CK5, is a marker of the basal phenotype of breast cancer. There was a strong relationship between reduced expression of BRCA1 with both p63 and CK5 expression as well as an inverse correlation between p63 and CK8/18 expression, suggesting that loss of p63 expression is required for the transition between a basal to a luminal phenotype of breast carcinoma. Conclusions : Since p63 is thought to be a marker of stem cells and may act as an oncogene, our data support the idea that BRCA1 acts as stem cell regulator.
引用
收藏
页码:458 / 466
页数:9
相关论文
共 37 条
[21]   Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker [J].
Reis, JS ;
Schmitt, FC .
ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (05) :280-283
[22]   Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast - An analysis of 82 samples [J].
Reis, JS ;
Milanezi, F ;
Amendoeira, I ;
Albergaria, A ;
Schmitt, FC .
CANCER CYTOPATHOLOGY, 2003, 99 (03) :172-179
[23]   Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray [J].
Reis, JS ;
Simpson, PT ;
Martins, A ;
Preto, A ;
Gärtner, F ;
Schmitt, FC .
VIRCHOWS ARCHIV, 2003, 443 (02) :122-132
[24]  
Rhodes A, 2002, AM J CLIN PATHOL, V118, P408
[25]  
Ribeiro-Silva A, 2003, ARCH PATHOL LAB MED, V127, P336
[26]   Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? [J].
Ribeiro-Silva, A ;
Ramalho, LNZ ;
Garcia, SB ;
Zucoloto, S .
PATHOLOGY & ONCOLOGY RESEARCH, 2003, 9 (01) :20-23
[27]   p63 is a prostate basal cell marker and is required for prostate development [J].
Signoretti, S ;
Waltregny, D ;
Dilks, J ;
Isaac, B ;
Lin, D ;
Garraway, L ;
Yang, A ;
Montironi, R ;
McKeon, F ;
Loda, M .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (06) :1769-1775
[28]   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].
Sorlie, T ;
Perou, CM ;
Tibshirani, R ;
Aas, T ;
Geisler, S ;
Johnsen, H ;
Hastie, T ;
Eisen, MB ;
van de Rijn, M ;
Jeffrey, SS ;
Thorsen, T ;
Quist, H ;
Matese, JC ;
Brown, PO ;
Botstein, D ;
Lonning, PE ;
Borresen-Dale, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874
[29]  
Stefanou D, 2004, HISTOL HISTOPATHOL, V19, P465, DOI 10.14670/HH-19.465
[30]  
Tavassoli FA, 2003, WHO CLASSIFICATION T, P13